Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ardelyx Inc
(NQ:
ARDX
)
6.350
+0.300 (+4.96%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ardelyx Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
ARDX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Ardelyx, Inc. Investors Can Join the Class Action Lawsuit!
Today 16:00 EDT
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 21, 2024
From
Schall Law
Via
GlobeNewswire
ARDELYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ardelyx, Inc. and Encourages Investors to Contact the Firm
August 20, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Ardelyx, Inc. Investor Notice: Robbins LLP Reminds Shareholders of the Pending ARDX Class Action
August 20, 2024
From
Robbins LLP
Via
Business Wire
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with the Schall Law Firm
August 19, 2024
From
The Schall Law Firm
Via
Business Wire
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx
August 19, 2024
From
Faruqi & Faruqi, LLP
Via
Business Wire
Rosen Law Firm Urges Ardelyx, Inc. (NASDAQ: ARDX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
August 19, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
Stockholder Alert: Robbins LLP Informs Ardelyx, Inc. Stockholders of the Class Action Against ARDX
August 18, 2024
From
Robbins LLP
Via
GlobeNewswire
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
August 08, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Second Quarter 2024 Financial Results and Provides Business Update
August 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Announces Publication of Two Plain Language Summaries from XPHOZAH® (tenapanor) Clinical Trials in Current Medical Research and Opinion
July 31, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report Second Quarter 2024 Financial Results on August 1, 2024
July 18, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, AAKP and NMQF File Lawsuit to Protect Dialysis Patient Choice and Timely Access to Clinically Meaningful Medicines
July 17, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
To Preserve Patient Access to XPHOZAH®, Ardelyx Chooses Not to File for TDAPA
July 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
June 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 30, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
May 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 21, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 16, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
May 14, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference
May 07, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
May 02, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH® (tenapanor) for Adults with Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
May 01, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
April 18, 2024
Conference call scheduled for 4:30 p.m. Eastern Time
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
March 28, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
March 25, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx, Inc. Reports Employment Inducement Grants
March 12, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Recent Market Movers: Healthcare Companies Making Headlines: DYAI, RIGL, ARDX, VERO, MEDS
February 28, 2024
Via
AB Newswire
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
February 27, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 22, 2024
From
Ardelyx, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.